February 10-11, 2014 The Waldorf Astoria New York

February 10-11, 2014
The Waldorf Astoria New York
Now in its sixteenth year, the BIO CEO & Investor Conference is the largest independent investor
conference focused on leading publicly-traded biotech companies, with a special focus on select established
private companies. The meeting provides a neutral forum where institutional investors, industry analysts,
and senior biotechnology executives have the opportunity to shape the future investment landscape of the
biotechnology industry.
Top
10
-2-
Reasons
to attend
1
35% of the biotechs who filed an IPO in 2013 will be presenting at this year’s
BIO CEO & Investor Conference.
2
Hear the Washington perspective on the Affordable Care Act and other
timely policy developments affecting the industry.
3
valuate fresh investment opportunities including compatible, complementary
E
and competitive companies.
4
L earn about the hottest clinical developments and industry catalysts by
attending the conference’s therapeutic workshops and business roundtables.
5
Attend fireside chats with CEOs who will share their recent company successes,
what keeps the C-suite up at night, and where the industry’s leading companies
are headed in 2014.
6
Gain access to BIO’s 1x1 Partnering SystemTM for scouting potential investments and
deal partners, optimizing your time at the event.
7
ear presentations from more than 150 established public and private biotech
H
companies and non-profit funding organizations, including many you won’t hear
from at other investor conferences.
8
Get the pulse of the current and proposed investment trends in biotechnology.
9
Network with peers, investors, and potential partners attending the conference
and our exclusive receptions.
Who Should Attend?
Audience Profile
Conference Size1,400
One-on-One PartneringTM
Meetings1,350+
Investors Attending
700
Company Presentations
150
Market Cap
>$1B+: 9%
300+ companies
Nearly 700 investors
<50M
24%
500M-1B
8%
250-500M
16%
50-100M
20%
100-250M
23%
Rare/Genetic
Diseases: 2%
Gastrointestinal
Ophthalmology Disorders: 2%
2%
Vaccines: 2%
Diagnostics: 2%
Therapeutic Focus
Renal: 3%
Metabolic: 4%
Oncology
29%
Cardiovascular
4%
Infectious
Diseases: 6%
Cell Therapy/
Regenerative
Medicine: 6%
Other
10%
Autoimmune/
Inflammation: 6%
CNS
13%
Over 1,400 attendees
from 20 different countries
Over 35% of attendees
are executives
Platform/
Discovery: 9%
-3-
Fireside Chats
Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other
high-level industry experts. Hear about recent company successes, what keeps the C-suite up at night, and
where the industry’s leading companies are headed in 2014.
Leonard Bell, M.D.
CEO, Alexion Pharmaceuticals
Belén Garijo, M.D.
President & CEO
Merck Serono
Richard F. Pops
Chairman & CEO
Alkermes plc
David E.I. Pyott
Chairman of the Board & CEO
Allergan
Christopher A. Viehbacher
CEO, Sanofi
Chairman, Genzyme
-4-
Plenary Sessions
Opening Remarks
• James C. Greenwood, President & CEO, Biotechnology Industry Organization
Opening Plenary: A Room with a (Buy-Side) View: The Year Ahead
Monday, February 10th, 12:00pm – 12:55pm
Join us for a scenic view of 2014 with portfolio managers and senior buy-side analysts. This lively panel
discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry
Analysis Team and International Strategy & Investment (ISI). Panelists will field a range of questions on the
peaks and valleys of the 2014 landscape, from valuations and volatility to challenges and opportunities facing
institutional investors today.
Moderator:
• Mark Schoenebaum, MD, Senior Managing Director, ISI Group
Panelists:
• Andrew Acker, CFA, Portfolio Manager, Janus Global Life Sciences
• Oleg Nodelman, Founder & Managing Director, EcoR1 Capital
• William S. Slattery, Partner, Deerfield Management Company
Closing Plenary: Fundraising in the New Capital Market Environment
Tuesday, February 11th, 4:00pm – 4:55pm
2013 was clearly the year of the IPO. As a result, a dynamic fundraising environment emerged last year.
Many biotechs took full advantage of this market to raise capital - through follow-ons and PIPEs after their initial
debut. What’s next? What challenges will await these newly public companies in 2014, or those private biotechs
waiting in the wings? Hear industry experts discuss why the markets are doing well and what effect it has had on
the entire biotech ecosystem. What’s their advice on how can we keep the momentum, and what do biotech CEOs
need to look out for in 2014?
Moderator:
• Jonathan L. Kravetz, Chair of the Securities Practice Group, Mintz Levin
Panelists:
• John Chambers, Managing Director, Head of Healthcare Investment Banking, ROTH Capital Partners
• David-Alexandre Gros, MD, Executive Vice President, Chief Strategy Officer, Sanofi
Speakers added daily.
-5-
Therapeutic Workshops
Delivering the [RNAi] Goods
Monday, February 10th, 10:30am - 11:25am
Investing in the RNA space? What delivery technology will win the race to turn these novel molecules into approved therapies? Is there a “winner take all” in this space or does each type of nucleic acid technology require a
unique platform for delivery? This panel will discuss ongoing innovation in the nanoparticle, liposomal, nucleic
acid, and conjugate-based approaches to delivering one of the most promising modalities in biotech.
Panelists:
• Douglas Fambrough, PhD, CEO, Dicerna Pharmaceuticals
• Bruce Given, MD, Chief Operating Officer, Arrowhead Research Corporation
• John Maraganore, PhD, Chief Executive Officer, Alnylam Pharmaceuticals
• Kleanthis G. Xanthopoulos, PhD, President & CEO, Regulus Therapeutics
Balancing the Risk-Reward in Rare Disease Drug Development
Monday, February 10th, 2:00pm – 2:55pm
There were certainly positive developments in the rare diseases space last year – as we saw with the success of
recent IPOs and new deals. These possibilities of large returns often outweigh the inherent risk involved, and
while the path to approval is not always as straightforward as it seems, success is there to be had. Challenges also
exist throughout development however, from validating endpoints and reimbursement costs, to the difficulties
of trial recruitment. How do you navigate this dynamic environment? CEOs of companies paving the way will be
on-hand to discuss the advantages and challenges involved in bringing rare disease treatments to market, and
industry experts will dissect some of the myths that have revolved around the space.
Panelists:
• Timothy R. Coté, MD, MPH, Principal & CEO, Coté Orphan Consulting
• Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa
Keeping an “I” on Oncology: The ASCO Immunotherapy Preview
Tuesday, February 11th, 1:30pm – 2:25pm
Immuno-oncology has been earning the spotlight over the past year, having been named as Science’s
Breakthrough of the Year, and this year’s ASCO will be no exception. Expert panelists will discuss the latest
developments in the immuno-oncology space. What will be the talk of ASCO? What does it take to get
breakthrough status? Why has this field taken so long to come to fruition? Are immunotherapies the answer
to managing cancer over a lifetime?
Panelists:
• Annalisa Jenkins, MBBS, MRCP, Executive VP & Head of Global Research and Development, Merck KGaA
• Michael G. King, Jr., Senior Analyst, Biotechnology, JMP Securities
• Anthony S. Marucci, Founder, President, CEO & Director, Celldex Therapeutics
• Jon Wigginton, MD, Senior Vice President, Clinical Research, MacroGenics
-6-
Business Roundtables
Solution Development: Aiming the Whole Pipeline at a Single Goal
Monday, February 10th, 9:00am - 9:55am
One model for maximizing biotech value creation is ‘Solution Development’, which calls for a company to develop
multiple agents for a single overarching indication, either to identify the best one of many or to develop combinations.
The panel will contrast this Solution Development model against the traditional model of developing a single drug for a
single indication or multiple drugs but for disparate indications. How will using a Solution Development model impact
clinical/regulatory strategy, competitive positioning, financing strategy, and M&A game theory?
Moderator:
• Peter Kolchinsky, PhD, Managing Director, RA Capital Management, LLC
Panelists:
•C
hristopher Anzalone, PhD, President & CEO, Arrowhead Research Corporation
• Stanley C. Erck, President & CEO, Novavax
•M
ilind S. Deshpande, PhD, President & CEO, Achillion Pharmaceuticals
• Kurt Graves, Chairman, President & CSO, Intarcia Therapeutics
The Reimbursement Landscape Under ACA
Tuesday, February 11th, 12:00pm – 12:55pm
The Affordable Care Act brings a great promise to the biotech industry and our nation as a whole. Now, a couple
months in, what do we know? What pressure will ACA put on the forces that impact product reimbursement, and how
will those forces respond? What can the biomedical ecosystem do to protect the industry’s pipelines? How did – and
have - companies prepared? Come hear a discussion among industry representatives on this new environment under
ACA, and get their take on where the law will lead one of the most important elements of biotech development.
Panelists:
• J.D. Kleinke, Healthcare Business Strategist
• Laurel Todd, Managing Director, Reimbursement & Health Policy, BIO
Let’s Make a Deal – Strategic Licensing and M&A Trends
Tuesday, February 11th, 9:00am - 9:55am
This panel will evaluate licensing and M&A trends of recent deals as the parties involved aim to get the biggest bang for their
buck. Why have these trends developed and what is in store for the future? What do small company executives and investors
think about recent valuations, CVRs, and the timing of deals with respect to stage of development? Hear industry experts
speak on the differing licensing challenges and solutions facing both large and small companies.
Moderator:
• Effie Toshav, Partner, Fenwick & West LLP
Panelists:
• Michael Diem, Global Vice President & Head of Corporate Strategy, AstraZeneca
Speakers added daily.
-7-
Agenda*
Duke of
Windsor
Conrad
Monday,
February 10, 2014
Park South
Basildon
4th Floor
East Foyer
Jade/Astor
3rd Floor
8th Floor
7:00 – 7:55am
Networking Breakfast (Grand Ballroom)
8:00 – 8:45am
Fireside Chat with Richard F. Pops, Chairman & CEO, Alkermes plc (Astor)
9:00 – 9:25am
Galena
Biopharma
Celator
Pharmaceuticals
9:30 – 9:55am
Agenus
NovaBay
Pharmaceuticals
10:00 – 10:25am
CytoDyn
Synthetic
Biologics
10:30 – 10:55am
Mast
Therapeutics
Prima BioMed
11:00 – 11:25am
Innovus
Pharmaceuticals
Cyclacel
Pharmaceuticals
Opexa
Therapeutics
Immune
Pharmaceuticals
11:30 – 11:55am
1x1 (1 & 2)
Intrexon
Corporation
Auxilium
Pharmaceuticals
Relypsa
Prosensa
Regado
Biosciences
ZIOPHARM
Oncology
Covagen
Proteon Therapeutics
Sutro Biopharma
Mirna Therapeutics
Cerecor
KemPharm
Epilepsy Foundation
(PAG)
ALS TDI (PAG)
Ultragenyx
Pharmaceutical
KineMed
OncoMed
Lexicon
Pharmaceuticals Pharmaceuticals
Onconova
Therapeutics
Synergy
Pharmaceuticals
Northwest
Biotherapeutics
Karo Bio AB
Business
Roundtable:
Solution
Development:
Aiming the
Whole Pipeline at
a Single Goal
(Jade)
1x1 (3)
1x1 (4)
1x1 (5)
Therapeutic
Workshop:
Delivering the
(RNAi) Goods
(Jade)
1x1 (6)
1x1 (7)
1x1 (8)
Opening Plenary Session: A Room with a (Buy-Side) View: The Year Ahead (Astor) – Box Lunch
12:00 – 12:55pm
1:00 – 1:25pm
Affimed
Kids V Cancer (PAG)
1x1
Timeslots
Anavex Life
Sciences Corp.
Melanoma Research
Alliance (PAG)
NeoStem
Conatus
Pharmaceuticals
Mesoblast
1x1 (11)
ImmunoCellular
Therapeutics
Navidea
Biopharmaceuticals
1x1 (12)
Immune Design
GenSpera
Resverlogix
2:00 – 2:25pm
Newron
Pharmaceuticals
S.p.A.
Anthera
Pharmaceuticals
DARA BioSciences
Five Prime
Therapeutics
Rigel
Pharmaceuticals
2:30 – 2:55pm
StemCells
CytRx
Corporation
Rexahn
Pharmaceuticals
BioLineRx
Stallergenes
3:00 – 3:25pm
Soligenix
TG Therapeutics
Stem Cell Therapeutics
Biotie Therapies
Progenics
Pharmaceuticals
3:30 – 3:55pm
Immunovaccine
GTx
Amarantus
BioScience
Alcobra
Repros
Therapeutics
4:00 – 4:25pm
Celsus
Therapeutics
Galectin
Therapeutics
Tonix
Pharmaceuticals
OncoSec Medical
Keryx
Biopharmaceuticals
4:30 – 4:55pm
La Jolla
Pharmaceutical
Company
Sorrento
Therapeutics
Intra-Cellular Therapies
Chimerix
Bavarian Nordic
A/S
5:00 – 6:30pm
-8-
Probiodrug AG
1:30 – 1:55pm
Speakers added daily.
Nuron Biotech
BIO CEO Reception (Empire Room)
Therapeutic
Workshop:
Balancing the
Risk-Reward in
Rare Disease
Drug
Development
(Jade)
1x1 (13)
1x1 (14)
1x1 (15)
Fireside Chat:
Christopher A.
Viehbacher
CEO, Sanofi
(Astor)
1x1 (16)
1x1 (17)
1x1 (18)
Tuesday,
February 11, 2014
Duke of
Windsor
4th Floor
Conrad
Park South
Basildon
East Foyer
Jade/Astor
3rd Floor
8th Floor
7:00 – 7:55am
Networking Breakfast (Grand Ballroom)
8:00 – 8:45am
Fireside Chat with David E.I. Pyott, CEO and Chairman of the Board, Allergan (Astor)
8:30 – 8:55am
Tekmira
Pharmaceuticals
Trovagene
9:00 – 9:25am
Benitec
Biopharma
Retrophin
9:30 – 9:55am
Apricus
Biosciences
Columbia
Laboratories
10:00 – 10:25am
Cytokinetics
SYGNIS AG
10:30 – 10:55am
Novelos
Therapeutics
Aradigm
Corporation
Opsona Therapeutics
Nora Therapeutics
Argos Therapeutics
Polynoma
Aduro BioTech
Kadmon Corporation
Melinta Therapeutics
TxCell SA
CymaBay Therapeutics
MaxCyte
1x1
Timeslots
1x1 (20/21)
Ophthotech
Exelixis
Ohr
Pharmaceutical
AcelRx
Pharmaceuticals
pSiVida
Arena
Pharmaceuticals
SciClone
Pharmaceuticals
Gilead Sciences
1x1 (25)
Inovio
Pharmaceuticals
OvaScience
1x1 (26)
Heat Biologics
ProMetic Life
Sciences
Stemline
Therapeutics
Regulus
Therapeutics
1x1 (22)
Business
Roundtable:
Let’s Make a
Deal – Strategic
Licensing and
M&A Trends
(Jade)
1x1 (23)
1x1 (24)
Trevena
11:00 – 11:25am
TiGenix N.V.
11:30 – 11:55am
RXi
Pharmaceuticals
12:00 – 12:55pm
(Box Lunch)
OXiGENE
Immunocore
Cleveland
BioLabs
Pieris AG
XDx
Business Development:
The Reimbursement Landscape Under ACA (Jade)
Fireside Chat:
Leonard Bell,
MD, CEO,
Alexion
(Astor)
1x1 (27)
1x1 (28)
Fireside Chat:
Belén Garijo, MD, President and CEO,
Merck Serono (Astor)
1x1 (29)
1:00 – 1:25pm
Catalyst
Pharmaceutical
Partners
ReNeuron
Group plc
Codexis
BIND
Therapeutics
Cempra
1:30 – 1:55pm
SIGA
Technologies
Advanced Cell
Technology
MetaStat
KaloBios
Pharmaceuticals
Alnylam
Pharmaceuticals
2:00 – 2:25pm
GENFIT
Athersys
Ignyta
Horizon Pharma
Swedish
Orphan
Biovitrum AB
2:30 – 2:55pm
AntriaBio
Targacept
Selvita S.A.
Idera
Pharmaceuticals
Orexigen
Therapeutics
1x1 (33)
3:00 – 3:25pm
DiaMedica
Neuralstem
CEL-SCI Corporation
Tetraphase
Pharmaceuticals
Verastem
1x1 (34)
3:30 – 3:55pm
Biodel
Transition
Therapeutics
Advaxis
Epizyme
PDL
BioPharma
1x1 (35)
1x1 (30)
Therapeutic
Workshop:
Keeping an “I”
on Oncology:
The ASCO
Immunotherapy
Preview
(Jade)
4:00 – 4:55pm
Closing Plenary: Fundraising in the New Capital Market Environment (Astor)
5:00 – 6:00pm
Closing Happy Hour (Silver Corridor)
1x1 (31)
1x1 (32)
Blue: Private Company • PAG: Patient Advocacy Group
* As of 1/15. Program schedule subject to change. Please go to www.bio.org/bioceo or visit us onsite for updates.
-9-
Presenting Companies
Sold Out!
The 2014 BIO CEO & Investor Conference will better accommodate the growing diversity of investors and
companies. While the majority of presenting companies at this event are publicly traded, with about half
trading with market capitalizations above $100M, this meeting with once again feature a unique track of
30 high-caliber and established private company presentations.
Presenting Companies*
PUBLIC COMPANIES
AcelRx Pharmaceuticals
Advanced Cell Technology
Advaxis
Agenus
Alcobra Pharma
Alexion Pharmaceuticals
Alkermes plc
Allergan
Alnylam Pharmaceuticals
Amarantus BioScience
Holdings
Anavex Life Sciences Corp.
Anthera Pharmaceuticals
AntriaBio
Apricus Biosciences
Aradigm Corp.
Arena Pharmaceuticals
Athersys
Auxilium Pharmaceuticals
Bavarian Nordic A/S
Benitec Biopharma
BIND Therapeutics
Biodel
BioLineRx
Biotie Therapies Corp.
Catalyst Pharmaceutical
Partners
Celator Pharmaceuticals
CEL-SCI Corporation
Celsus Therapeutics
Cempra
Chimerix
Cleveland BioLabs
Codexis
Columbia Laboratories
Conatus Pharmaceuticals
Cyclacel Pharmaceuticals
CytoDyn
Cytokinetics
CytRx Corporation
DARA BioSciences
DiaMedica
-10-
Epizyme
Exelixis
Five Prime Therapeutics
Galectin Therapeutics
Galena Biopharma
GENFIT
GenSpera
Gilead Sciences
GTx
Heat Biologics
Horizon Pharma
Idera Pharmaceuticals
Ignyta
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunovaccine
Innovus Pharmaceuticals
Inovio Pharmaceuticals
Intra-Cellular Therapies
Intrexon Corporation
KaloBios Pharmaceuticals
Karo Bio AB
Keryx Biopharmaceuticals
La Jolla Pharmaceutical
Company
Lexicon Pharmaceuticals
Mast Therapeutics
Merck Serono
Mesoblast
MetaStat
Navidea Biopharmaceuticals
NeoStem
Neuralstem
Newron Pharmaceuticals
S.p.A.
Northwest Biotherapeutics
NovaBay Pharmaceuticals
Novelos Therapeutics
OHR Pharmaceuticals
OncoMed Pharmaceuticals
Onconova Therapeutics
OncoSec Medical
Opexa Therapeutics
Ophthotech
Orexigen Therapeutics
OvaScience
OXiGENE
PDL BioPharma
Prima BioMed
Progenics Pharmaceuticals
ProMetic Life Sciences
Prosensa
pSivida Corp.
Regado Biosciences
Regulus Therapeutics
Relypsa
ReNeuron Group plc
Repros Therapeutics
Resverlogix Corp.
Retrophin
Rexahn Pharmaceuticals
Rigel Pharmaceuticals
RXi Pharmaceuticals
Sanofi
SciClone Pharmaceuticals
Selvita S.A.
SIGA Technologies
Soligenix
Sorrento Therapeutics
Stallergenes
Stem Cell Therapeutics
StemCells
Stemline Therapeutics
Swedish Orphan Biovitrum AB
SYGNIS AG
Synergy Pharmaceuticals
Synthetic Biologics
Targacept
Tekmira Pharmaceuticals
Corporation
Tetraphase Pharmaceuticals
TG Therapeutics
TiGenix N.V.
Tonix Pharmaceuticals
Transition Therapeutics
Trovagene
Verastem
ZIOPHARM Oncology
PRIVATE COMPANIES
Aduro BioTech
Affimed Therapeutics
ALS Therapy Development
Institute
Argos Therapeutics
Cerecor
Covagen
CymaBay Therapeutics
Epilepsy Foundation
Immune Design Corporation
Immunocore
Kadmon Corporation
KemPharm
Kids v Cancer
KineMed
MaxCyte
Melanoma Research
Alliance
Melinta Therapeutics
Mirna Therapeutics
Nora Therapeutics
Nuron Biotech
Opsona Therapeutics
Pieris AG
Polynoma
Probiodrug
Proteon Therapeutics
Sutro Biopharma
Trevena
TxCell SA
Ultragenyx
XDx
* As of 01/14/2014
Participating Investors
Participating Investors*
Up 60% over
last year!
21st Century Investors
Aceras Biomedical
Aegis Capital Corp.
Akana Healthcare Capital
American Capital
Amici Capital
AmTrust Financial
Anson Group Canada
Arcus Ventures
Arthritis Foundation
Ascendant Capital
Aspire Capital Partners
Athyrium Capital Management
Atika Capital Management
Atlantis Investment
Atlas Capital
ATP Early Harvest Fund
Auriga Capital Management
Avior Capital
AZCA Venture Partners
Bank of America Merrill Lynch
Barclays
Bawcap
Bayshore Venture
BDC Healthcare Fund
Bergmor Capital
Bijan Capital
Bill and Melinda Gates
Foundation
Biotech Stock Review
BioYields
Black Diamond
Bloom Burton & Co.
BNY Mellon
BofAML
Boodell & Co
Brean Capital
Burrage Capital
Burrill & Company
Cantor Fitzgerald
Capital Royalty
Cato BioVentures
Cedarlane Enterprises inc
Cedrus Investments
China Private Equity Group,
Crown Point Group
Dabar Investment Associates
Dalek Capital Management
Eachwin Capital LP
Early Harvest Fund
Easton Capital
EcoR1 Capital
Edgewood Management
Edison Investment Research
EGB Advisors,
Emerald Advisers, Inc.
Empire Asset Management
Ennovance Capital
F.B.Asset Management
Favus Institutional
Research
FireRock Capital
First Island Capital
First Manhattan Company
Five Corners Capital Inc.
Fountain Healthcare Partners
GE Capital, Life Science
Finance
Global Corporate Finance
Global Energy Capital
Goldman Sachs
Greenwich LifeSciences
Griffin Securities
Halcyon Cabot Partner
Hercules Technology Growth
Capital
HI Investors Capital
Horizon Technology Finance
Hutchin Hill Capital
Iliad Ventures
IS Ceske Sporitelny
Jina Ventures Inc.
JMP Securities
Johnston Associates
JPMorgan
Knoll Capital Management
Korea-Seoul Life Science
Fund (KSLSF)
Ladenburg Thalmann
Laidlaw & Company
Landmark Angels, Inc.
LFP Capital
Life Science Ventures
LifeScience EquityPartners,
LifeTech Capital
Lincoln Park Capital
Little Gem Life Sciences
Livingston Securities
Loeb Partners
Logical Ventures
Loncar Family
Long Wharf Investors, Inc.
LSWorks
Lumira Capital
Magna Group Capital
Markston International
Maxim Group
Maz Capital Advisors
Medimmune Ventures, Inc.
MedPro Investors
Mehta Partners
Merck
MFP Investors
Midfarm Capital
Mitsui Global Investment
Mizuho Securities
Morgan Stanley
Mountain Brook Capital
Management LLC
MP Healthcare Venture
Management, Inc.
MSF Capital Advisors
MVP Capital Partnera
Needham & Company
NGN Capital
NJ Investment Division
Nordcon Capital
Numoda Capital Innovations
On-Point Capital
Oppenheimer & Co. Inc.
Opus Point Partners
Oracle Investment
Management
OrbiMed Advisors
Outer Islands Capital
Oxford Finance
Pacific Rim Ventures
Palkon Capital Management
Pappas Ventures
Piper Jaffray
Poliwogg
Profit Investments
Questrion
QVT Financial
Rockefeller & Co.
Rocker Funder
ROTH Capital Partners
Roy Healthcare Research
RTW Investments
RusBio Ventures
Samtheo Biopharma
Sands Capital
Serrado Capital
SimRx
Sio Capital Management
Slater Technology Fund
SLC Management
Small Business Technology
Investment Fund
Somerset Capital Group, Ltd.
Spencer Edwards Investment
Stanphyl Capital
Stifel
Strategy Signal
Stuyvesant Capital
Management
Sunrise Equity Partners
Symmetry Capital
Symphony Capital
Syzygy Therapeutics
TaiAn Technologies
Technological & Investment
Horizons
Tegris Advisors
The Channel Group
The Issaquena Trust
The Keiser Foundation
Tryphon
UBS
US Steel Pension Fund
V2M Capital
Valquest Capital Management
VAO Partmers
Var2 Pharmaceuticals
venBio
Venrock
Veziris Ventures
Visium
Watervein Partners, Inc.
WBB Securities
Weiss Multi-Strategy
Advisers
Wexford Capital LP
Wolf Capital Management
World Tech Ventures
*As of 01/14/2014
-11-
One-on-One Meetings
BIO’s One-on-One Partnering™ System is the interactive environment that allows you to increase your
productivity, discover new investment and licensing opportunities, and expand your business potential
worldwide. Using the system, companies are able to:
• Pre-schedule 30-minute private 1x1 meetings
• Source potential collaborations and funding opportunities with an international audience
• Communicate directly with prospective investors and C-level executives in biotech and pharma
• Search company and investor profiles for potential business partnerships
One-on-One Partnering Statistics
1,380 scheduled meetings
in 2013
72% growth in scheduled
meetings since 2009
1,600
Company to Investor
91%
Total Scheduled Meetings
1,400
-12-
Investor to Investor
3%
1,380
1,210
1,200
1,000
800
931
801
600
400
200
0
Company to Company
6%
1,327
2009
2010
2011
Year
2012
2013
Sponsors
Supporting Bank Sponsors
BIO Double Helix Sponsors
BIO Helix Sponsors
Conference Supporters
Media Sponsors
Local Co-Host
BIO sponsors receive top-notch customer service, prime brand exposure and recognition from
the most influential people in biotech. Let us build a sponsorship package that meets your needs.
Contact George MacDougall at 202-292-6689 or gmacdougall@bio.org to get started.
For more information on BIO sponsorships, please visit www.bio.org/sponsor
-13-
Advisory Committee
Tom Brakel, MD
Senior Portfolio Manager &
Senior Investment Analyst,
Federated Kaufmann Funds
John Chambers
Managing Director & Head of Healthcare
Investment Banking, ROTH Capital Partners
Bernard Davitian
Vice President & Managing Director
Sanofi-Genzyme BioVentures
Michael Hay
Vice President, BioMedTracker Product
Manager, Sagient Research Systems
Annalisa Jenkins, MBBS, MRCP
Executive VP and Head of Global Research
and Development, Merck KGaA
Peter Kolchinksky, PhD
Managing Partner, RA Capital Management, LLC
Arlene Morris
CEO, Syndax Pharmaceuticals
Oleg Nodelman
Founder & Managing Director, EcoR1 Capital
David Sable, MD
Portfolio Manager, Special Situations
Life Sciences Fund
Hans GCP Schikan, PharmD
Nathan Tinker, PhD
Executive Director
New York Biotechnology Association
-14-
CEO, Prosensa
Reserve your spot today!
3 BIO offers a number of ways for conference attendees to save money
on their registration fees.
3 Discounted packages for presenting companies bringing three or more attendees.
3 Special rates for academics and service providers.
Complimentary registration is available to qualified institutional (buy and sell-side),
private equity, and venture investors.
Go to bio.org/bioceo/register and register now.
REGISTRATION CATEGORIES
FEES
PRESENTER GROUP PACKAGES* FEES
Member
Member Additional
Non-Member
Non-Member Additional
Service Provider Member
Service Provider Non-Member
Academic/Tech Transfer
$2,095
$1,595
$2,795
$2,795
$4,195
$5,195
$895
Public Group Member
Public Group Non-Member
Private Group Member
Private Group Non-Member
$6,795
$9,195
$5,595
$7,795
PRESENTATION FEES
FEES
Member Public
Non-Member Public
Member Private
Non-Member Private
$2,895
$3,795
$1,895
$2,595
* Includes presentation and registration fees.
Hotel Venue
The Waldorf Astoria New York
301 Park Avenue
New York, NY 10022
A limited number of rooms are
available at the Waldorf Astoria.
Please make your reservations
as soon as possible to secure
your room at the discounted rate.
Join the conversation:
Learn more about Biotechnology at bio.org
Engage with the Biotech Community at BIOtech-NOW.org
Follow us on Twitter @bio1x1 or #BIOCEO14
Become a fan on Facebook (facebook.com/IAmBiotech)
-15-